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CLINICAL ARTICLES
Stage-Specific Manifestation of Mold Infections in Bone Marrow Transplant
Recipients: Risk Factors and Clinical Significance of Positive Concentrated
Smears
Kwok-Yung Yuen, Patrick C. Y. Woo, Mary S. M. Ip, From the Department of Microbiology and the Department of Medicine,
The University of Hong Kong, Queen Mary Hospital, Hong KongRaymond H. S. Liang, Edmund K. W. Chiu, Hong Siau,
Pak-Leung Ho, Frederick F. E. Chen,
and Tai-Kwong Chan
Potassium hydroxide–concentrated smears, prepared from sedimented remains of clinical speci-
mens, were used to distinguish between mold infection and exogenous contamination in fungal
culture–positive specimens. This method was applied in the study of 3,857 clinical specimens
from 230 bone marrow transplant recipients who were followed up prospectively for infectious
complications. Concentrated smears of only 86 (from 21 infected patients) of 149 fungal culture–
positive specimens were positive for hyphae; 82 of the strains were Aspergillus species. Concentrated
smears of the remaining 63 fungal culture–positive specimens were negative; the strains identified
by culture were considered as exogenous contaminants (87% of which were Penicillium species). A
stage-specific manifestation of mold infection was observed: 67% of mold infections occurred during
acute graft-vs.-host disease (GVHD) a median of 47 days after transplantation, whereas 9% of mold
infections occurred as rapidly fatal invasive disease before engraftment. Overall, of the 21 patients
with mold infection, 17 (81%) had invasive mold disease, and four (19%) had mold colonization of
airways secondary to chronic GVHD after day 100. The significant risk factors for mold infection
were total-body irradiation and grade 2–4 acute GVHD. Because of our high mortality rate (82%),
the consideration of antimold prophylaxis for such patients may be warranted.
Since the last decade, molds are gaining prominence as op- in the environment and are often disregarded in cultures of
portunistic pathogens. In immunocompetent hosts, molds rarely nonsterile specimens such as sputum, urine, stool, and superfi-
cause serious illnesses, except for indwelling device–associ- cial swabs. In the absence of clinical evidence, the presence
ated infections, posttraumatic mycetoma, aspergilloma in pa- of molds in these specimens usually indicates contamination
tients with preexisting chronic lung diseases, and self-limiting by fungal spores during collection and processing or coloniza-
diffuse pneumonitis after massive inhalation of spores. How- tion of fungal spores on damaged airways, mucosal lesions,
ever, molds cause life-threatening diseases in immunosup- and superficial skin [5].
pressed hosts, especially patients with AIDS, neutropenic pa- Several laboratory criteria (e.g., the presence of characteristic
tients, and solid organ and bone marrow transplant (BMT) fungal elements in smears and multiple cultures of the same
recipients [1, 2]. Most invasive diseases due to molds are species) have been proposed to exclude exogenous contamina-
caused by Aspergillus species. In one study [3], infections with tion. However, the sensitivity of detection by smear examina-
this mold occurred in 8.7% of allogeneic BMT patients. In tion is low, and consecutive specimens for culture are usually
another study [4], the mortality rate associated with aspergillus not available. The sensitivity or specificity of alternative diag-
infection in patients with pulmonary involvement and persistent nostic approaches, such as the detection of fungal antigens or
neutropenia was 95%. DNA amplification, has also been found to be low [6].
The successful management of mold infections is hampered The definitive diagnosis of invasive disease requires the iso-
by difficulties in establishing diagnoses. Molds are ubiquitous lation of mold in culture and histological demonstration of its
presence [7]. Yet, in one study [8], the predictive value of
positive cultures of respiratory tract specimens from neutro-
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smear as a rapid and sensitive diagnostic tool to differentiate spectively prepared and examined; only concentrated smears
of BAL fluid specimens were prepared directly and examined.genuine mold infection from contamination. A prospective
study of 3,857 clinical specimens from 230 BMT patients was Before microscopic examination and culture of the speci-
mens were performed, respiratory secretions were pretreatedconducted; direct and concentrated smears of fungal culture–
positive specimens were prepared and examined. The clinical with Sputasol (Oxoid, Basingstoke Hampshire, United King-
dom), and tissue biopsy specimens were homogenized in mi-correlation of positive concentrated smears, the temporal se-
quence of the onset of infection, and the risk factors for mold crofuge tubes containing PBS. For microscopic examination,
tissue biopsy specimens were further digested in 20% (w/v)infections were analyzed. The results of this study are presented
herein. KOH solution at 377C for 15 minutes. To prepare a direct KOH
smear by wet mounting, 20 mL of the specimen was mixed
with an equal volume of 20% KOH solution, placed on a glass
slide, and mounted under a coverslip. The slide was screened atPatients and Methods
low-power magnification (1100) under dark-field illumination;
septate hyaline hyphae with uniform diameters (4 mm) andPatients and antimicrobial prophylaxis. Two hundred
thirty patients who underwent bone marrow transplantation at dichotomous branching at 457 were highly suggestive of Asper-
gillus.the Queen Mary Hospital in Hong Kong during a 5-year period
(1991–1995) were included in this study. Before transplanta- Each specimen was inoculated onto two plates with Sabour-
aud dextrose agar supplemented with chloramphenicol (50tion, all patients were admitted to protective isolation rooms
with high efficiency particulate air filtration [9]. Patients who mg/L); the plates were incubated at 257C and 377C. The re-
mains of each specimen were kept at 47C for 2 weeks beforewere receiving BMTs from mismatched siblings or matched
unrelated donors (MUDs) were admitted to rooms that were disposal. Mold isolates were identified by standard morphologi-
cal criteria [13]. The day on which positive growth was visuallyalso equipped with laminar airflow [10]; these patients under-
went total-gut decontamination with tobramycin (80 mg q.i.d.), observed and the site and number of cfu on the agar were
recorded.vancomycin (500 mg q.i.d.), and nystatin (10 mL q.i.d.).
From day 0 until stable engraftment, all patients were treated The corresponding refrigerated clinical sample of the fungal
culture–positive specimen was retrieved for the preparation ofwith chlorhexidine mouthwash, amphotericin B lozenges, ci-
profloxacin (500 mg b.i.d.), and acyclovir (200 mg t.i.d.) concentrated smears. The maximal amount of each specimen
was digested in an equal volume of 20% KOH solution and[11, 12]. When patients developed neutropenia and fever, they
were treated empirically with iv imipenem/cilastin (10 mg/kg centrifuged at 5,000 rpm for 10 minutes at room temperature.
Swab specimens positive for fungi were vortexed in Eppendorfq6h). If fever persisted for 48 hours and the workup for sepsis
was negative, iv vancomycin (10 mg/kg q6h) was added to tubes containing PBS to recover fungal elements and concen-
trated by centrifugation. All but 100 mL of the supernatantthe treatment. On the fifth day of neutropenia and fever, iv
amphotericin B therapy (0.5 mg/[kgrd]) was initiated. If mold fluid was decanted; an aliquot of the fluid was mounted on a
glass slide and examined as described above.infection was documented or suspected on clinical and microbi-
ological grounds, the dosage of amphotericin B was increased Definitions. Invasive mold disease was defined either by
culture and histological examination of a biopsy or autopsyto 1.5 mg/(kgrd).
All patients undergoing allogeneic or MUD transplantation tissue specimen revealing mold or by culture and examination
of a direct smear showing mold, a compatible clinical andreceived the following as prophylaxis for acute graft-vs.-host
disease (GVHD): 15 mg of iv methotrexate/m2 on day 1; 10 radiological picture, and no response to antibacterial therapy.
A positive culture without documented evidence of invasivemg of iv methotrexate/m2 on days 3, 6, and 11; and 5 mg of
oral cyclosporine/kg b.i.d. from day 1 to day 50 or 1.5 mg of disease could be due to colonization or exogenous contamina-
tion. Acute myeloid leukemia and acute lymphoblastic leuke-iv cyclosporine/kg q12h from day 1 to day 50 when the patient
could not tolerate oral medication. mia in the first complete remission, chronic myeloid leukemia
in chronic phase, lymphoma in the first complete remission,Microbiological methods. One week before and up to 1.5
years after transplantation or until death, each patient’s medical myeloma in complete remission, and severe aplastic anemia in
patients younger than 25 years of age who were not receivingprogress was recorded, and clinical specimens from each pa-
tient were collected. Routine surveillance cultures of stool, immunosuppressive therapy were considered as early underly-
ing diseases. Any other underlying diseases were considerednasal swabs, and throat swabs were performed weekly to detect
fungi and multidrug-resistant bacteria. All respiratory secre- as late diseases.
Data analyses. A comparison of microbiological character-tions, including sputa, endotracheal aspirates, and bronchoal-
veolar lavage (BAL) fluids, were cultured for bacteria, myco- istics between concentrated smear–positive, fungal culture–
positive specimens and concentrated smear–negative, fungalbacteria, Legionella, and fungi. Direct smears of only tissue
and respiratory specimens undergoing fungal culture were pre- culture–positive specimens was performed by the x2 test. Uni-
variate logistic analysis was performed to identify risk factorspared for microscopic examination for mold. Concentrated
smears of all fungal culture–positive specimens were retro- for infections by molds. On the basis of the results of the
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univariate logistic analysis, variables with P values of .05 or median period from inoculation to detection of visible growth
for the concentrated smear–positive specimens was 3 daysthose known to be biologically important were included in a
multivariate logistic analysis. The backward elimination less than that for the concentrated smear–negative specimens.
Multiple colonies were growing on the agar for all concentratedmethod was used to select variables. The importance of each
factor to the model was assessed by the likelihood ratio; a two- smear–positive specimens; these colonies were all found on
the primary streak line. In addition, 12 specimens from patientstailed x2 test was used to determine this ratio.
with invasive diseases who were receiving antifungal therapy
were culture-negative but concentrated smear–positive, a find-
Results
ing with implications for therapeutic monitoring (these implica-
tions are reviewed under Discussion).Fungal cultures of 149 of 3,857 clinical specimens (of which
1,072 were derived from febrile neutropenic patients) were During the study period, 21 (9%) of 230 BMT patients had
culture-documented infection by molds (table 2). These infec-positive; concentrated smears of 86 of these 149 fungal cul-
ture–positive specimens were positive for mold (table 1). Not tions were diagnosed a median of 67 days after transplantation.
Invasive diseases occurred in 17 patients (81%), while fourunexpectedly, there was an absolute correlation between the
results of the examinations of concentrated smears and those (19%) had colonization. The respiratory tracts of these four
patients were colonized with Aspergillus species (one withof the examinations of the direct smears. Several statistically
significant differences (P  .05) were noted between concen- three Aspergillus species) after day 100, and all four did not
have evidence of mold infection earlier in their clinical coursestrated smear–negative specimens and concentrated smear–
positive specimens. Concentrated smear–positive specimens when they were neutropenic.
Most of the infections were caused by Aspergillus flavuswere taken mainly from sinopulmonary sites or biopsied
tissues. (38%), Aspergillus fumigatus (19%), and other Aspergillus spe-
cies (28%). The lung and paranasal sinuses (86%) were theMost isolates (95%) from concentrated smear–positive spec-
imens were Aspergillus species, while 87% and 3% of the predominant sites of infection [14]. Extrasinopulmonary infec-
tions involved the brain, skin and soft tissue, gastrointestinalfungal isolates from concentrated smear–negative specimens
were Penicillium and Aspergillus species, respectively. The tract, and ear. Most infections occurred after engraftment (me-
Table 1. Comparison of results of examinations of concentrated smears of clinical specimens from
BMT recipients that were positive for mold by culture.
Culture-positive specimens
Concentrated smear– Concentrated smear–
Result positive (n  86) negative (n  63) P value*
No. of patients (no. of specimens) 21 (402) 209 (3,455)
No. of patients with positive direct KOH smears
(no. of specimens) 7 (29) 0 (0) .0001
No. of indicated culture-positive specimens
Respiratory secretion (sputum, ETA, BAL fluid) 49 2 .0001
Nasal discharge or swab 13 11 NS
Throat swab 0 18 .0001
Stool or rectal swab 2 20 .0001
Tissue 10 0 .05
Others† 12 12 NS
No. of specimens with indicated isolates
Aspergillus species‡ 82 2 .0001
Fusarium species 2 0 NS
Penicillium species 1 55 .0001
Others§ 1 6 NS
Median duration (d) until visible growth (range) 2 (1–4) 5 (1–12)
Presence of mold on Sabouraud dextrose agar
Single colony 11 48 .0001
Multiple colonies on primary streak line 86 18 .0001
NOTE. BAL  bronchoalveolar lavage; BMT  bone marrow transplant; ETA  endotracheal aspirate; NS 
not significant.
* Statistical analysis by the x2 test.
† Includes antral washout, ear discharge, wound swab, catheter tip, and urine.
‡ Multiple species of Aspergillus were isolated from some specimens.
§ Includes Acremonium species and members of Mycelia sterilia.
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Table 2. Clinical characteristics of 21 BMT recipients with mold Three patients received additional treatment with oral itracona-
infections. zole (600 mg/d for 3 days and then 400 mg/d until death)
because of poor response to amphotericin B therapy. Despite
Characteristic Value*
treatment of these 17 patients, 14 (82%) died of mold infection
and uncontrolled GVHD. The underlying diseases in theseMedian duration (d) until diagnosis (range) 67 (0–634)
Type of mold infection patients were in remission. Only three patients infected with
Invasive mold disease 17 (81) Penicillium funiculosum, Acremonium falciforme [15], and
Colonization, invasive disease doubtful 4 (19) Fusarium solani, respectively, survived. Their neutrophil
Type of mold isolated
counts at the onset of infection were 1.5 1 109/L, and twoAspergillus flavus 8 (38)
received granulocyte macrophage colony-stimulating factorAspergillus fumigatus 4 (19)
Other Aspergillus species 6 (28) therapy for augmentation of phagocytic function. Of the four
Fusarium solani 1 (5) patients who were colonized with Aspergillus, three received
Penicillium funiculosum 1 (5) oral itraconazole therapy for 2 weeks. None of these patients
Acremonium falciforme 1 (5)
had additional evidence of invasive disease, despite continuousOrgan(s) involved†
isolation of Aspergillus from their sputa.Lung 13 (62)
Paranasal sinuses 5 (24) The possible risk factors for infection by molds are presented
Brain 3 (14) in table 3. Univariate logistic analysis found that acute lymph-
Skin and soft tissue 2 (10) oblastic leukemia, MUD, total-body irradiation (TBI), and
Gastrointestinal tract 1 (5)
grade 2–4 GVHD were significant risk factors. However,Ear 1 (5)
multivariate logistic analysis revealed that only TBI and gradeMedian time (d) of onset of infection (range) 47 (0–634)
Infection before engraftment 2 (9) 2–4 GVHD were significant risk factors.
Infection after engraftment during the period
of acute GVHD 14 (67)
Infection after engraftment during the period Discussion
of chronic GVHD 5 (24)
The differentiation of infection from exogenous contamina-Concomitant infection
Cytomegalovirus 11 (52) tion by mold is often difficult but would be lifesaving in the
Bacteria‡ 7 (33) setting of bone marrow transplantation. We used concentrated
Concomitant neutropenia (neutrophil count, smears of fungal culture–positive specimens to distinguish be-500 1 109/L) 4 (19)
tween the two entities and found that the presence of character-Death due to invasive mold disease 14/17 (82)
istic hyphae was often detected in clinically compatible cases
NOTE. BMT  bone marrow transplant; GVHD  graft-vs.-host disease. (table 1). This finding was expected since the concentrated
* Unless otherwise stated, data are no. (%) of patients. smear in effect screened the entire specimen for the presence† More than one organ was involved in four patients.
of the mold, while only a fraction of the specimen was inocu-‡ Includes methicillin-resistant Staphylococcus aureus, coagulase-negative
staphylococci, Streptococcus pneumoniae, Pseudomonas aeruginosa, Pseu- lated for culture.
domonas cepacia, Mycobacterium avium/Mycobacterium intracellulare com- Examination of concentrated smears for hyphae is rapid, andplex, and Mycobacterium chelonae.
the entire field of the smear can be completely evaluated for
these large fungal elements at a magnification of 1100 within
2 minutes. However, it would not be practical and cost-effectivedian time of onset of infection, 47 days); 14 patients (67%)
were receiving immunosuppressive treatment for acute GVHD. to incorporate this method into routine mycology procedures
because there would be a tremendous increase in the workOnly two patients with severe neutropenia (9%) developed
infection before engraftment; both had severe diffuse pulmo- load. Therefore, immediate preparation and examination of
concentrated smears of specimens from patients suspected ofnary disease with extrapulmonary dissemination. Thirteen pa-
tients (62%) developed neutropenia and fever early after trans- having mold infection or of selected specimens (e.g., BAL
fluid) would definitely help in establishing a diagnosis earlier.plantation, but none of these patients had any other clinical or
radiological evidence of invasive disease. Concomitant cyto- Furthermore, the concentrated smear may also be useful in
monitoring the progress of treatment, since cultures becomemegalovirus (CMV) disease occurred in 11 patients; these pa-
tients received ganciclovir therapy. Two of these 11 patients less sensitive after the initiation of antifungal therapy.
After ascertaining the value of the concentrated smear, wedeveloped severe neutropenia secondary to ganciclovir therapy
just before the onset of invasive mold disease and required explored the clinical aspects and possible implications for
mold infection. A stage-specific pattern of mold infectiontherapeutic support with growth factors; however, none of these
patients became more neutropenic after the diagnosis of mold was found. Most mold infections occurred after engraftment
during the period of acute GVHD; only two of the 17 episodesdisease.
Of the 17 patients with invasive mold disease, 14 were of invasive disease with extrasinopulmonary dissemination
occurred in the neutropenic period during the first 30 days, andtreated with iv amphotericin B (1–1.5 mg/[kgrd]), and three
were treated with iv liposomal amphotericin B (3 mg/[kgrd]). colonization of airways in four patients with chronic GVHD
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Table 3. Possible risk factors for mold infections in BMT recipients.
Infected BMT Uninfected BMT
Risk factor recipients (n  21) recipients (n  209) P value
Male:female ratio 13:8 120:89 NS
Mean age in y (range) 29 (1–43) 28 (0.25–54) NS
No. (%) with diagnosis
Acute myeloid leukemia 8 (38) 59 (28) NS
Acute lymphoblastic leukemia 8 (38) 21 (10) .05*
Chronic myeloid leukemia 3 (14) 62 (30) NS
Lymphoma 0 26 (12) NS
Others 2 (10) 41 (20) NS
No. (%) with stage of underlying disease
Early 9 (43) 92 (44) NS
Late 12 (57) 117 (56) NS
No. (%) with indicated transplant
Allogeneic 15 (71) 156 (75) NS
Autologous 0 34 (16) NS
Match unrelated donor 6 (29) 16 (8) .05*
Syngeneic 0 3 (1) NS
No. (%) with conditioning regimen
With TBI 19 (90) 108 (52) .005*†
Cyclophosphamide 5 (23) 40 (20)
Busulfan and cyclophosphamide 9 (43) 54 (26)
Melphalan 1 (5) 3 (1)
Etoposide and cyclophosphamide 4 (19) 11 (5)
Without TBI 2 (10) 101 (48)
Busulfan and cyclophosphamide 1 (5) 55 (26)
Cyclophosphamide, busulfan, and etoposide 1 (5) 25 (12)
Others 0 (0) 21 (10)
Mean duration (d) of neutropenia‡ { SEM 18.8 { 1.2 21.4 { 0.6 NS
No. (%) with indicated acute GVHD
Grade 0–1 3 (14) 126 (60) NS
Grade 2–4 18 (86) 83 (40) .05*†
NOTE. BMT  bone marrow transplant; GVHD  graft-vs.-host disease; NS  not significant; TBI  total-
body irradiation.
* By univariate logistic analysis.
† By multivariate logistic analysis.
‡ Engraftment failed in two patients in the infected group and in 11 patients in the uninfected group; these patients
were not included in the analysis.
manifested as bronchiolitis obliterans after day 100. The me- tients [17]. The incidence of mold infection decreased after day
120. The lower risk of invasive disease in patients with chronicdian time of the onset of mold infection in our patients was
47 days, a period comparable with that (42 days) reported in GVHD than in those with acute GVHD could be associated with
the relatively smaller doses of immunosuppressive therapy as wella previous study [16].
The emergence of this pattern of mold infection might be as with the relatively lower rate of CMV infection (and therefore
less need for ganciclovir therapy).associated with the policy for and practice of antifungal therapy
in our hospital. Antifungal prophylaxis during the preen- Infection by molds, especially Aspergillus species, is an increas-
ing problem in most tertiary care hospitals. Known risk factorsgraftment period and the early use of amphotericin B as empiri-
cal treatment for neutropenia and fever on day 5 might have (in the order of decreasing importance) are prolonged severe neu-
tropenia, neutrophil and/or macrophage dysfunction, steroid ther-prevented the onset of overt mold infection in most of our
patients during the preengraftment period. apy, GVHD or graft rejection, and its associated treatment
[18–20]. Like other investigators, we found that grade 2–4 acuteAfter engraftment, no routine antifungal prophylaxis was given
to patients who were receiving pulse steroid and cyclosporine GVHD was important [21]. However, more interestingly, TBI
was found to be another independent risk factor for mold infec-therapy for acute GVHD. The risk of mold infection was increased
further by the transfer of these patients from protective isolation tions (table 2). To our knowledge, TBI has never been directly
recognized as a significant risk factor for mold infection, althoughrooms to general wards after engraftment and by the mild neutro-
penia (neutrophil count, 500 to 1,500 1 109/L) associated it has been cited as a risk factor for increased development of
invasive fungal infection in granulocytopenic patients [22].with ganciclovir therapy for CMV disease in some of these pa-
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4. Denning DW, Stevens DA. Antifungal and surgical treatment of invasiveThe use of TBI may reflect the severity of the underlying
aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:malignancy, or in effect, TBI may impose additional immuno-
1147–201.
suppression on patients. Since BMT patients undergoing TBI 5. Sinski JT. The epidemiology of aspergillosis. In: Yousef A-D, ed. The
have a greater risk of developing mold infection, we propose epidemiology of human mycotic disease. 1st ed. Springfield, Illinois:
that this group of patients should receive antimold prophylaxis Charles C. Thomas, 1975:210–6.
6. Verweij PE, Latge J-P, Rijs AJMM, et al. Comparison of antigen detectionduring acute GVHD.
and PCR assay using bronchoalveolar lavage fluid for diagnosing inva-The incidence of culture-documented mold infection in our
sive pulmonary aspergillosis in patients receiving treatment for hemato-
hospital approached 10%, which is comparable with that (8.7%)
logical malignancies. J Clin Microbiol 1995;33:3150–3.
reported in a previous study [3]. However, the incidence of 7. Wong K, Waters CM, Walesby RK. Surgical management of invasive
mold infection in this study could be underestimated. An aspect pulmonary aspergillosis in immunocompromised patients. Eur J Cardio-
thorac Surg 1992;6:138–42.not analyzed in this study was the absence of fungal growth
8. Treger TR, Visscher DW, Bartlett MS, Smith JW. Diagnosis of pulmonaryin specimens from patients with focal pulmonary lesions. There
infection caused by Aspergillus: usefulness of respiratory cultures. J
were six patients who were treated empirically for possible
Infect Dis 1985;152:572–6.
pneumonia due to mold in the absence of a positive culture of 9. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991;
BAL fluid. They did not consent to an open lung biopsy because 18(suppl A):466–72.
10. Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosisthe operative risk was considered unacceptable. This non-
by laminar air-flow isolation. J Hosp Infect 1989;14:89–94.compliance for further invasive testing could not be overlooked
11. Chan TK, Chiu EKW. Bone marrow transplantation in Hong Kong. Pro-
since most Chinese patients are reluctant to undergo diagnostic
ceedings of the Royal College of Physicians of Edinburgh 1993;23:
operative procedures and postmortem examinations. 170–7.
In this prospective study of fungal culture–positive speci- 12. Chiu EKW, Yuen P, Chan TK. Bone marrow transplantation in Hong
Kong. Bone Marrow Transplant 1994;13:713–5.mens from BMT recipients, Aspergillus was the most important
13. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manualpathogen. Unlike most previous reports [14, 23], A. flavus,
of clinical microbiology. 6th ed. Washington, DC: American Societyinstead of A. fumigatus, was the dominant isolate. This occur-
for Microbiology, 1995.
rence might be a regional phenomenon (as reported by other 14. Young RC, Jennings A, Bennett JE. Species identification of invasive
investigators [24]) or might be related to the use of methotrex- aspergillosis in man. Am J Clin Pathol 1972;58:554–7.
15. Lau YL, Yuen KY, Lee CW, Chan CF. Invasive Acremonium falciformeate prophylaxis for GVHD, since this agent is known to inhibit
infection in a patient with severe combined immunodeficiency [letter].the germination of spores of A. fumigatus but not those of
Clin Infect Dis 1995;20:197–8.A. flavus [25]. The most frequent environmental contaminant
16. Meyers JD. Fungal infections in bone marrow transplant patients. Semin
was Penicillium species. Similar findings were obtained by Oncol 1990;17(3)(suppl 6):10–3.
routine environmental sampling (data not shown). The only 17. Yuen K-Y, Lo SK-F, Chiu EK-W, et al. Monitoring of leukocyte cytomeg-
Penicillium species that was isolated and associated with inva- alovirus DNA in bone marrow transplant recipients by nested PCR. J
Clin Microbiol 1995;33:2530–4.sive disease was P. funiculosum, a finding consistent with its
18. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA.ability to grow at 377C and its minute-sized conidia (which are
Prolonged granulocytopenia: the major risk factor for invasive pulmo-
known virulence factors of mold [26]).
nary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;
In conclusion, concentrated smears are useful for differenti- 100:345–51.
ating infection from exogenous contamination by mold. Before 19. Ng TTC, Robson GD, Denning DW. Hydrocortisone-enhanced growth of
Aspergillus spp.: implications for pathogenesis. Microbiology 1994;empirical antifungal therapy is considered for patients whose
140:2475–9.specimens are concentrated smear–negative but culture-posi-
20. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risktive (especially for Aspergillus), multiple additional specimens
factor for invasive aspergillosis in patients with lung disease. Thorax
should be retaken and examined. Furthermore, the documenta- 1991;46:15–20.
tion of an increased risk of mold infection in patients receiving 21. O’Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic
fungal infection in allogeneic marrow recipients: impact of amphotericintreatment for acute GVHD who do or do not have histories of
prophylaxis in high-risk patients. J Clin Oncol 1994;12:827–34.TBI may be important in targeting those patients who should
22. Walsh TJ, Hiemenz J, Pizzo PA. Editorial response: evolving risk factorsreceive antifungal prophylaxis.
for invasive fungal infections—all neutropenic patients are not the
same. Clin Infect Dis 1994;18:793–8.
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